IMU-838

Phase 3Small molecule

IImmunic AG

IMU-838 is one of 34 small molecule programs targeting Multiple Sclerosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple SclerosisActive, not recruiting

Multiple SclerosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

145 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

1 2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

9 3

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 4

Zyrtec

KKenvue Brands

Phase 3

1 5

Frexalimab

Sanofi

Phase 3

2 6

Clemastine Fumarate

Novartis

Phase 3

2 7

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

Phase 3

1 8

MRI Contrast-Enhancing Agents

Sanofi

Phase 3

3 9

IMU-838

IImmunic AG

Phase 3

4 10

Flomax

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Active, not recruiting

Multiple Sclerosis

NCT03846219

Q3 2033

Phase 3Active, not recruiting

Multiple Sclerosis

NCT05134441

Q4 2033

Phase 3Active, not recruiting

Multiple Sclerosis

NCT05201638

Clinical

Trials by Indication[1]

Multiple Sclerosis4 trials

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

Active, not recruiting·IImmunic AG·Phase 2·NCT03846219·210 enrolled

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Active, not recruiting·IImmunic AG·Phase 3·NCT05134441·1,121 enrolled

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Active, not recruiting·IImmunic AG·Phase 3·NCT05201638·1,100 enrolled

Show 1 more trial

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Active, not recruiting·IImmunic AG·Phase 2·NCT05054140·450 enrolled

COVID-192 trials

A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)

Completed·IImmunic AG·Phase 2/3·NCT04379271·234 enrolled

IMU-838 and Oseltamivir in the Treatment of COVID-19

Completed·UUniversity Hospitals Coventry and Warwickshire NHS Trust·Phase 2·NCT04516915·38 enrolled

Ulcerative Colitis1 trial

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

Terminated·IImmunic AG·Phase 2·NCT03341962·263 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for IMU-838. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMU-838 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMU-838. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immunic AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IImmunic AG

IMU-838

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q3 2033

Q4 2033

Trials by Indication[1]

Multiple Sclerosis4 trials

COVID-192 trials

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News